NCT02388464View on ClinicalTrials.gov

A Study Investigating the Safety, Tolerability, and Pharmacokinetics of MTP-131 in Subjects With Congestive Heart Failure

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

April 30, 2015

Study Completion Date

June 30, 2015

Conditions
Congestive Heart Failure
Interventions
DRUG

MTP-131

MTP-131 (low dose) administered as single intravenous infusion over 4 hours

DRUG

MTP-131

MTP-131 (intermediate dose) administered as single intravenous infusion over 4 hours

DRUG

MTP-131

MTP-131 (high dose) administered as single intravenous infusion over 4 hours

DRUG

Placebo

Placebo Comparator (at each dose cohort) administered as single intravenous infusion over 4 hours

Trial Locations (1)

Unknown

Sevlievo

All Listed Sponsors
lead

Stealth BioTherapeutics Inc.

INDUSTRY

NCT02388464 - A Study Investigating the Safety, Tolerability, and Pharmacokinetics of MTP-131 in Subjects With Congestive Heart Failure | Biotech Hunter | Biotech Hunter